Business Context and Reporting Period
This Form 8-K filing by Lucid Diagnostics Inc. (LUCD) covers the event date of February 24, 2025. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC. The filing addresses the company's compliance status with Nasdaq listing requirements.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance regarding stock price.
Material Changes
The primary material event is the restoration of compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement.
- Previous Status: On June 21, 2024, the company received notice that its stock price had been below $1.00 for 30 consecutive business days.
- Compliance Period: The company was granted an initial 180-day period to regain compliance, followed by an additional 180-day extension granted on December 19, 2024, extending the deadline to June 16, 2025.
- Current Status: Nasdaq confirmed that from February 7, 2025, to February 21, 2025, the closing bid price of the common stock was at or above $1.00 per share.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks or contingencies beyond the resolution of the listing deficiency. The unusual item addressed is the prior delinquency in meeting the minimum bid price, which has now been resolved.
Investor Verification Checklist
- Verify the current trading price of LUCD to ensure it remains at or above the $1.00 minimum bid price to avoid future delisting notices.
- Confirm the company's status as an emerging growth company, which may affect financial reporting disclosures.
- Review subsequent filings for any updates on the company's operational progress or financial health, as this 8-K contains no financial data.